AstraZeneca-Daiichi breast-cancer drug Enhertu approved for routine use in England
NICE approved Enhertu for routine use in England after changing its recommendation following the U.S.-U.K. pharmaceutical-pricing deal.
AstraZeneca and Daiichi Sankyo's breast-cancer drug Enhertu has been approved by the drug-cost watchdog for routine use in England, after the regulator changed its recommendation following the U.S.-U.K. pharmaceutical-pricing deal. The National Institute for Health and Care Excellence…